Biocon and Mylan's cancer biosimilar gets CHMP nod for approval in EU

The CHMP opinion for the drug to be sold under the named Fulphila will now be considered by the European Commission and the decision on approval is expected by November

from Latest News https://ift.tt/2PVgeJ6
https://ift.tt/eA8V8J https://ift.tt/2LUVdkd

• Tweet
• Share
• Share
• Share
• Share